Practical Clinical Guidance : How to deal with node positive MIBC ? Incorporates latest developments in Bladder cancer
Muscle-invasive bladder cancer (MIBC)
with lymph node involvement represents one of the most challenging treatment
scenarios in UK oncology practice. Clinically node-positive (cN+)
non-metastatic MIBC carries significantly worse prognosis than node-negative
disease, with 5-year overall survival (OS) of only 30-32% compared to 85% in
responders without nodal spread[1]. The management of these patients demands
careful multidisciplinary assessment and individualized treatment planning to
optimize outcomes whilst balancing quality of life considerations.
This comprehensive review synthesises
current evidence from major international guidelines (NCCN, ASCO, ESMO, EAU)
and Cochrane meta-analyses to provide practical recommendations for UK clinical
teams, with particular emphasis on recent therapeutic breakthroughs and
systemic therapy approvals in 2024-2025.
Prognostic Significance of Node-Positive Disease
Baseline Prognosis and Risk
Stratification
The
presence of lymph node metastases fundamentally alters the natural history of
MIBC. Each additional positive node—up to 4-6 nodes—is associated with
progressively lower survival rates[2]. Node-positive disease, even in the
absence of distant metastases, represents occult systemic disease with high
propensity for later distant dissemination[3].
Key prognostic factors in cN+ MIBC
include[4]:
•
Number
of positive nodes (single vs multiple)
•
Extent
of nodal involvement (N1 vs N2-3)
•
Primary
tumour stage (T2 vs T3-4a)
•
Response
to neoadjuvant chemotherapy (NAC) with downstaging to pN0
•
Pathological
complete response (pCR) achievement
•
Presence
of extensive or multifocal carcinoma in situ
•
Performance
status and comorbidity burden
Contemporary Evidence on Outcomes
Recent large retrospective analyses
demonstrate significant outcome heterogeneity in cN+ patients[5]:
·
Median
OS ranges from 10% to 59% at 5 years depending on treatment received and
response
·
Patients
achieving downstaging from cN+ to pN0 following NAC demonstrate survival
improvement up to 44%
·
Extended
pelvic lymph node dissection (ePLND) template correlates with improved node
count assessment and prognostic accuracy
Core Treatment Modalities
and Current Evidence
1. Neoadjuvant Chemotherapy
(NAC) Followed by Radical Cystectomy with Extended PLND
Evidence Base
and Guideline Status
Platinum-based NAC followed by radical
cystectomy (RC) with extended pelvic lymph node dissection (ePLND) remains the
gold-standard curative approach for fit, chemotherapy-eligible cN+ MIBC
patients across all major guidelines (NCCN, ASCO, ESMO, EAU)[6].
Cochrane
Meta-Analysis Summary
A comprehensive Cochrane systematic
review and meta-analysis including 15 randomised controlled trials (3,285
patients) demonstrated[7]:
|
Outcome |
Pooled
HR |
95%
CI |
Absolute
Benefit |
|
Overall Survival (NAC vs
surgery alone) |
0.87 |
0.79–0.96 |
5–8% at 5 years |
|
Reduction in mortality
risk |
14% |
- |
- |
|
10-year OS (CMV regimen) |
36% |
vs
30% control |
+6% |
|
10-year DFS (CMV regimen) |
27% |
- |
- |
Table
1: Cochrane Meta-Analysis: NAC Efficacy in MIBC
Specific
Evidence in Node-Positive Disease
For cN+ patients specifically, NAC
followed by RC offers the best documented long-term survival outcomes. The
multicentre retrospective analysis by Necchi and colleagues demonstrated that
among 522 cN+ patients, post-IC (induction chemotherapy) RC with PLND versus
observation after IC showed significantly superior outcomes in appropriately
selected patients[8].
Recommended
NAC Regimens
|
Regimen |
Cycles |
Toxicity Profile |
Evidence |
|
Gemcitabine + Cisplatin
(GC) |
4 cycles (21-day) |
Well-tolerated, reduced
nephrotoxicity |
Preferred standard |
|
Dose-dense MVAC (ddMVAC) |
4 cycles (14-day) with
G-CSF |
Higher acute toxicity,
improved survival in phase III VESPER |
Alternative option |
|
CMV |
4 cycles |
Established legacy
regimen |
Historical standard |
Table
2: Neoadjuvant Chemotherapy Regimens
Cisplatin
Eligibility Assessment
Cisplatin ineligibility is defined by
meeting ANY ONE of the following criteria (Gupta criteria)[9]:
•
Eastern Cooperative Oncology Group (ECOG)
performance status ≥3
•
Creatinine clearance (CrCl) <30
mL/min/1.73m²
•
Peripheral neuropathy grade ≥2
•
New
York Heart Association (NYHA) class >3 congestive heart failure
•
Combination of ECOG ≥2 AND CrCl <30
mL/min/1.73m²
Approximately 50% of MIBC patients are
cisplatin-ineligible or limited-dose candidates, necessitating alternative
strategies[10].
Key Evidence
on NAC Safety
Importantly, recent large multicentre
retrospective analyses demonstrate that NAC does NOT increase perioperative
morbidity following RC. Post-operative complication rates are similar between
NAC-treated and surgery-only cohorts, and cystectomy completion rates remain
high (86-87%) even in NAC-treated populations[11].
2. Perioperative
Immunotherapy + Chemotherapy: The NIAGARA Paradigm
Landmark
NIAGARA Trial Data (FDA Approved March 2025)
The phase 3 NIAGARA trial
(NCT03732677), enrolling 1,063 cisplatin-eligible MIBC patients, demonstrated
for the first time that adding durvalumab to neoadjuvant chemotherapy
significantly improves outcomes[12]:
|
Outcome |
Durvalumab
+ Chemo |
Chemotherapy
Alone |
HR
(95% CI) |
|
Event-Free Survival at 24
months |
67.8% |
59.8% |
0.68 (0.56–0.82) |
|
Overall Survival at 24
months |
82.2% |
75.2% |
0.75 (0.59–0.93) |
Table
3: NIAGARA Trial: Perioperative Durvalumab + Chemotherapy
Mechanism and
Rationale
Durvalumab (anti-PD-L1) addresses the
immune checkpoint exhaustion seen in MIBC and may enhance chemotherapy efficacy
and prevent micrometastatic progression. The regimen combines:
·
Neoadjuvant: Durvalumab 1,500 mg IV
Q3W + gemcitabine/cisplatin (4 cycles maximum)
·
Adjuvant: Single-agent durvalumab
1,500 mg IV Q4W (maximum 8 cycles post-surgery)
Clinical
Implications
The NIAGARA regimen is now
FDA-approved (March 2025) and represents an important option for
cisplatin-eligible patients. However, it requires careful patient selection
regarding:
·
Increased
immune-related adverse event monitoring
·
Tumour
burden and surgical candidacy post-induction
·
Patient
preferences regarding additional toxicity vs marginal OS benefit
Landmark
KEYNOTE-905 Trial Data (FDA Approved November 2025)
The phase 3 KEYNOTE-905/EV-303 trial
enrolled 595 cisplatin-ineligible or declining MIBC patients and demonstrated
unprecedented efficacy of perioperative enfortumab vedotin (EV) +
pembrolizumab[13]:
|
Outcome |
EV
+ Pembrolizumab |
Surgery
Alone |
HR
(95% CI) |
|
Event-Free Survival |
Not
reached |
15.7
months |
0.40 (0.28–0.57) |
|
Overall Survival |
Not
reached |
41.7
months |
0.50 (0.33–0.74) |
|
Pathologic Complete
Response |
57.1% |
8.6% |
- |
|
Median EFS (months) |
NR |
15.7 |
p<0.0001 |
Table
4: KEYNOTE-905 Trial: Perioperative EV + Pembrolizumab in Cisplatin-Ineligible
MIBC
Mechanism of
Action
This combination represents a paradigm
shift away from chemotherapy dependence:
·
Enfortumab vedotin (Padcev): Anti-nectin-4
antibody-drug conjugate selectively targeting bladder cancer cells
·
Pembrolizumab (Keytruda): Anti-PD-1 immunotherapy
enhancing immune recognition
Treatment
Schedule
·
Neoadjuvant: EV 1.25 mg/kg IV days 1,
8 + pembrolizumab 200 mg IV day 1, Q3W for 3 cycles
·
Adjuvant: EV + pembrolizumab for 6
cycles + pembrolizumab monotherapy for additional 8 cycles
Importance
for UK Practice
This
is the FIRST perioperative regimen to demonstrate OS benefit in
cisplatin-ineligible MIBC patients—a previously neglected high-risk population
with only surgery as standard option. Following NHS England/NICE negotiations
(August 2025), the EV+pembrolizumab combination is now available on the NHS for
eligible patients. But currently the NICE approval is only for metastatic or
unresectable cases
4. Chemoradiotherapy (CRT)
with Bladder Preservation
Rationale and
Patient Selection
Trimodality therapy (maximal TURBT +
concurrent CRT + bladder preservation) offers organ-preserving alternative for
carefully selected patients who decline or are unsuitable for cystectomy.
Current guidelines recommend concurrent chemotherapy combined with EBRT as a
strong recommendation (Category 1)[14].
Optimal
Candidate Selection
•
Solitary
tumours without extensive or multifocal carcinoma in situ
•
Tumour
size <6 cm with negative nodes (cN0)
•
No
hydronephrosis
•
Ability
to achieve visibly complete or maximal debulking TURBT
•
Good
renal function (though not absolute contraindication to bladder preservation)
•
Patient
strongly motivated for bladder preservation
Important
Caveat for cN+ Disease
Current evidence for CRT in cN+ MIBC
is LIMITED. A single-institution phase 2 study of 38 patients with confirmed or
high-risk nodal involvement (60% cN+) treated with concurrent IMRT
achieved[15]:
•
Median
OS: 1.9 years
•
5-year
OS: 34%
•
Bladder
preservation rate: 85%
•
Late
Grade 3+ GI toxicity: 5%
Cochrane
Evidence on NAC Before CRT
A recent systematic review and
meta-analysis evaluating NAC followed by CRT versus CRT alone in MIBC (4
observational studies, 3,354 patients) found[16]:
|
Outcome |
NAC
+ CRT |
CRT
Alone |
p-value |
|
Overall Survival |
HR 0.99 (95% CI 0.87–1.13) |
- |
0.89 |
|
Disease-Free Survival |
HR 1.07 (95% CI 0.57–2.01) |
- |
0.82 |
Critical
Assessment:
The quality of evidence is very low (retrospective, selection/confounding
bias). No survival advantage for adding NAC to CRT was demonstrated, though
prospective randomised trials are needed for definitive conclusions.
Concurrent
CRT Chemotherapy Options
|
Regimen |
Schedule |
Evidence
Level |
|
Cisplatin-based
(preferred) |
70 mg/m² IV day 2, Q3W × 3 |
Strong
(Category 1) |
|
Gemcitabine + Cisplatin |
1000 mg/m² + 70 mg/m², Q3W × 3 |
Strong |
|
Low-dose Gemcitabine |
27 mg/m² twice-weekly (induction) |
Alternative
(NRG/RTOG 0712) |
|
Mitomycin C |
Radiosensitiser
option |
Limited
evidence |
Long-Term
Outcomes with NAC + CRT
A Canadian retrospective analysis of
57 MIBC patients (65% cT2, 25% cT3, 11% cN+) treated with NAC followed by CRT
bladder-preservation reported[17]:
•
Median
follow-up: 74.4 months
•
5-year
disease-free survival: 49%
•
5-year
bladder-intact DFS: 45%
•
5-year overall survival: 65% (95% CI
50.7–75.5%)
•
Local
recurrence: 19%
•
Salvage
cystectomy required: 16%
Treatment Decision-Making
Algorithm for cN+ Non-Metastatic MIBC
Patient-Centered Assessment
Framework
Effective treatment selection requires
integration of:
1.
Disease factors: Nodal extent (cN1 vs
cN2-3), T stage, presence of CIS, hydronephrosis, extent of TURBT
2.
Patient fitness: ECOG performance status,
renal function (CrCl), cardiac status, hearing, neuropathy
3.
Cisplatin eligibility: Formal assessment using
Gupta criteria
4.
Patient preferences: Organ preservation desire
vs curative intent prioritization
5.
Institutional capacity: Availability of expertise
in perioperative immunotherapy, complex urinary diversion, CRT delivery
Recommended Treatment Pathways
Pathway 1:
Cisplatin-Eligible cN+ MIBC (Patient Willing and Fit for RC)
Preferred
Option: NIAGARA Regimen (Durvalumab + NAC + RC)
Evidence: Highest-level evidence for
OS benefit in cisplatin-eligible patients. NIAGARA trial demonstrated 8.2% OS
benefit at 24 months.
Recommended
approach:
·
Durvalumab 1,500 mg IV Q3W × 4 cycles
(concurrent with chemotherapy, neoadjuvant phase)
·
Gemcitabine 1,000 mg/m² IV days 1, 8 +
Cisplatin 70 mg/m² IV day 2, Q3W × 4 cycles
·
Radical cystectomy with extended PLND (≥25
nodes goal)
·
Adjuvant
durvalumab 1,500 mg IV Q4W (maximum 8 cycles)
Key
management considerations:
·
Full
immunoglobulin and thyroid function monitoring during and after treatment
·
Ensure
baseline cardiac imaging given durvalumab use
·
Discuss
realistic pCR expectations (typically 30-40% with chemotherapy alone, higher
with durvalumab addition)
·
Establish
baseline urinary and sexual function given cystectomy impact
Alternative
Option: Standard NAC (Gemcitabine + Cisplatin) + RC
Evidence: Established standard with
robust meta-analytical support (5-8% OS benefit). Appropriate if patient
prefers to avoid additional immunotherapy toxicity or institutional experience
with NIAGARA limited.
Recommended
approach:
·
Gemcitabine 1,000 mg/m² IV days 1, 8 +
Cisplatin 70 mg/m² IV day 2, Q3W × 4 cycles
·
Radical
cystectomy with extended PLND
·
Consider
adjuvant nivolumab (CheckMate 275) if high-risk features present (pN+ or
high-grade LVI after surgery)
Pathway
2: Cisplatin-Ineligible cN+ MIBC (Recently Changed Paradigm—November 2025)
PREFERRED
OPTION: Perioperative EV + Pembrolizumab (KEYNOTE-905 Regimen)
Evidence: FIRST perioperative
non-chemotherapy regimen to demonstrate OS benefit in cisplatin-ineligible
MIBC. FDA approved November 2025. NHS available (August 2025 NICE approval).
Recommended
approach:
·
Perioperative enfortumab vedotin 1.25 mg/kg IV
days 1, 8 + pembrolizumab 200 mg IV day 1, Q3W × 3 cycles (neoadjuvant)
·
Radical
cystectomy with extended PLND
·
Adjuvant EV + pembrolizumab × 6 cycles, then
adjuvant pembrolizumab monotherapy × 8 cycles
Toxicity
profile requires specific counselling:
•
Skin
toxicity (rash, pruritus): 40-60% (often grade 1-2, manageable with dermatology
input)
•
Sensory/motor neuropathy: ~60% (dose-limiting
toxicity; cumulative over treatment course)
•
Ocular
keratitis: 20-30% (requires baseline ophthalmology and frequent monitoring)
•
Hyperglycaemia:
10-15% (glucose monitoring essential)
Strengths of
EV+pembrolizumab for cN+ cohort:
·
Does
NOT require cisplatin, overcoming renal/comorbidity limitations
·
Superior
pCR rates (57% vs 8% with surgery alone)
·
Consistent
benefit across all patient subgroups regardless of cisplatin eligibility
·
Manageable
toxicity profile with appropriate monitoring and dermatology/ophthalmology
support
Traditional
Alternative: Carboplatin + Gemcitabine (For Cisplatin-Ineligible Patients
Declining Immunotherapy)
Evidence: Established regimen in
metastatic setting; limited neoadjuvant data for MIBC.
Recommended
approach
(if EV+pembrolizumab unavailable/declined):
·
Gemcitabine 1,000 mg/m² IV days 1, 8 +
Carboplatin AUC 4-5 IV day 2, Q3W × 4 cycles
·
Radical
cystectomy with extended PLND
·
Consider
switch-maintenance avelumab if no progression (evidence mainly in metastatic
setting)
Note: Carboplatin-gemcitabine
is less well-studied than cisplatin-based regimens in MIBC and should be
considered second-line for cisplatin-ineligible patients now that
EV+pembrolizumab available.
Pathway 3: Strong Patient
Preference for Bladder Preservation (Suitable cN0 Disease Only)
Note: Limited
Evidence for cN+ Disease with CRT
CRT should generally NOT be first-line
for cN+ patients due to:
·
Highest
risk of occult systemic disease in node-positive cohort
·
Limited
long-term survival data in cN+ CRT cohorts
·
Difficulty
assessing residual nodal disease post-CRT
Recommended
approach if bladder preservation mandatory (cN0 disease selected):
·
Maximal
debulking TURBT
·
Neoadjuvant platinum-based chemotherapy × 4
cycles (gemcitabine/cisplatin preferred)
·
Concurrent
chemoradiotherapy:
o External beam radiotherapy:
64-70 Gy to primary tumour, 44 Gy to bladder/pelvis
o Concurrent chemotherapy: Cisplatin 70 mg/m² IV Q3W × 3 cycles OR
gemcitabine 1,000 mg/m² weekly × 6 weeks
·
Planned
cystoscopic surveillance at 4-8 weeks post-CRT with biopsy assessment
·
Salvage
cystectomy if residual MIBC or relapse
Inadequate
for cN+ Disease:
CRT alone without adequate chemotherapy and with cN+ disease carries
unacceptably high risk of systemic progression given occult micrometastatic
burden.
Pathway 4: Palliative
Systemic Therapy (Unresectable or Declining Surgery)
Indications
for Palliative Approach:
•
Extensive
cN2-3 disease deemed unresectable despite NAC
•
Patient
age/comorbidity prohibiting surgery despite chemotherapy tolerance
•
Patient
firm refusal of cystectomy despite counselling
First-Line
Options
(Metastatic-Stage Evidence, Applied to Advanced Non-Metastatic):
Option A:
Enfortumab Vedotin + Pembrolizumab (EV-302 Paradigm)
Evidence: Phase 3 EV-302 trial in
metastatic UC demonstrated superior OS vs platinum chemotherapy across all
subgroups, leading to FDA approval as first-line therapy (2024)[18].
|
Outcome |
EV
+ Pembrolizumab |
Platinum
Chemotherapy |
HR |
|
Overall Survival |
NR
(median) |
Median
14 months |
0.53–0.56 |
|
Progression-Free Survival |
NR |
Median
7-8 months |
0.43–0.48 |
|
Objective Response Rate |
60–78% |
35–53% |
- |
Recommended
approach:
·
Enfortumab
vedotin 1.25 mg/kg IV days 1, 8 + pembrolizumab 200 mg IV day 1, Q3W
·
Continue
until progression, unacceptable toxicity, or maximum 2 years
·
Robust
monitoring for dermatologic, ocular, and neuropathic toxicity
Option B:
Platinum-Based Chemotherapy (If EV+P Unavailable or Contraindicated)
Evidence: Standard of care in
platinum-eligible metastatic disease; less well-studied in advanced MIBC.
Recommended
regimen:
·
Gemcitabine 1,000 mg/m² IV days 1, 8 +
Cisplatin 70 mg/m² IV day 2, Q3W × 4-6 cycles
·
For cisplatin-ineligible: Gemcitabine 1,000
mg/m² + Carboplatin AUC 4-5, Q3W × 4-6 cycles
·
Followed
by switch-maintenance avelumab if no progression (JAVELIN Bladder-100
trial)[19]
Option C:
Single-Agent Immune Checkpoint Inhibitors (ICIs) (Less Preferred Monotherapy)
Evidence: Pembrolizumab approved for
cisplatin-ineligible metastatic UC (baseline); nivolumab approved for adjuvant
high-risk MIBC (CheckMate 275)[20].
Note: Single-agent ICI
monotherapy is generally inferior to combination approaches and should be
reserved for:
·
Patients with high PD-L1 expression (CPS ≥10)
declining chemotherapy
·
Patients
with contraindications to both chemotherapy and antibody-drug conjugates
·
Platinum-progression
scenarios
Special Considerations for
cN+ MIBC Management
Role of Extended Pelvic
Lymph Node Dissection (ePLND)
Extended template PLND should be
performed for all cN+ MIBC patients undergoing RC[21]:
•
Removes
obturator, iliac (external, internal, common), presacral, and retroperitoneal
nodes
•
Minimum goal: ≥25 lymph nodes removed
•
More
important than total node count: Template extension itself (ePLND vs limited)
•
Prognostic
impact: Downstaging from cN+ to pN0 associated with 44% OS improvement
•
Therapeutic
impact: May improve cure rates in appropriately selected patients with limited
nodal burden
Response Assessment and
Adjustment During NAC
Clinical
Response Evaluation:
·
Imaging
(CT/MRI) after 2 cycles to assess downstaging potential
·
Circulating
tumour DNA (ctDNA) emerging as biomarker for treatment response (research
setting)
·
Cystoscopic
re-evaluation not routine unless clinically indicated
Chemotherapy
Completion Rates:
·
85-95%
of patients complete planned NAC cycles
·
Dose
reductions/delays manageable with appropriate supportive care
·
NAC
completion should NOT be sacrificed for marginal time savings if patient
tolerating treatment
Traditional
Approach:
·
Adjuvant
chemotherapy (AC) for node-positive disease remains controversial
·
Meta-analyses
show marginal OS benefit, offset by treatment toxicity
·
AC
generally offered to patients with:
o pN+ disease after RC
o High-grade LVI
o Non-response to NAC (ypT2+)
o Good performance status
post-recovery
Emerging
Approach—Adjuvant Nivolumab (CheckMate 275):
·
FDA
approved 2021 for high-risk recurrence after RC
·
Recent
2024 data showed continued benefit in node-positive cohort
·
OS
benefit trend favourable even with immature data
NIAGARA
Adjuvant Durvalumab:
·
Integral to NIAGARA protocol (adjuvant
durvalumab × 8 cycles post-RC)
·
Should
not be abandoned even if chemotherapy toxicity during induction phase
Special Populations:
Cisplatin-Ineligible cN+ Patients
Pre-KEYNOTE-905
Landscape
(Prior to November 2025):
·
Cisplatin-ineligible
cN+ patients had NO established systemic regimen
·
Options
limited to carboplatin-gemcitabine (less effective) or surgery alone
·
Outcomes
markedly worse than cisplatin-eligible cohort
Post-KEYNOTE-905
Landscape
(November 2025 onwards):
·
Enfortumab
vedotin + pembrolizumab now first perioperative option for cisplatin-ineligible
cN+ MIBC if approved by NICE. Currently I am using it when there are multiple
pelvic nodes (>1) and I know that surgery will be declined even if excellent
response.
·
Landmark
trial demonstrated:
o 60% reduction in EFS events
vs surgery alone
o 50% reduction in mortality
vs surgery alone
o Benefit consistent across
all patient subgroups regardless of cisplatin eligibility
·
This
shifts paradigm: Cisplatin eligibility
becoming less relevant as decision-making criterion[22]
Practical Implementation in
UK Healthcare System
Multidisciplinary Team (MDT)
Assessment
Essential MDT discussion for all cN+
MIBC patients should include:
•
Medical
oncologist (chemotherapy/systemic therapy expertise)
•
Urologist
(surgical assessment, ePLND capability)
•
Radiologist
(imaging interpretation, staging accuracy)
•
Radiotherapist
(if considering CRT pathway)
•
Specialist
nurse (toxicity management, patient support)
•
Palliative
care specialist (if advanced disease)
Essential
Before Treatment Initiation:
•
Enhanced imaging: CT chest/abdomen/pelvis ±
MRI pelvis (staging)
•
Baseline
renal function: Calculated creatinine clearance (Cockcroft-Gault or MDRD)
•
Baseline
audiometry (cisplatin cumulative ototoxicity)
•
Baseline
neuropathy assessment (NCI CTCAE v5.0 grading)
•
Cardiac
assessment: LVEF if durvalumab or EV+pembrolizumab planned
•
Baseline
ophthalmology examination (if EV+pembrolizumab planned)
•
Glucose
and HbA1c (EV+pembrolizumab hyperglycaemia risk)
Chemotherapy-Related
Supportive Care:
•
Prophylactic
antiemetics (5-HT3 antagonist, NK1 antagonist, dexamethasone)
•
Hydration
protocols (especially cisplatin-based regimens)
•
Growth
factor support (G-CSF) if needed for dose-dense regimens
•
Renal
function monitoring: Baseline, before each cycle, minimum CrCl >30
Immunotherapy-Specific
Supportive Care
(NIAGARA, KEYNOTE-905):
•
Thyroid
function monitoring: Pre-treatment baseline, monthly during treatment, then 3-6
monthly post-treatment
•
Regular
immunoglobulin levels if recurrent infections developing
•
Dermatology
co-management for rash/pruritus (EV+pembrolizumab especially)
•
Ophthalmology
monitoring for keratitis (EV+pembrolizumab baseline and q4-6 weeks)
•
Glucose
monitoring and diabetes management (EV+pembrolizumab)
•
Neuropathy
assessment and grading (EV+pembrolizumab cumulative dose-limiting toxicity)
Treatment Pathway Selection:
Practical UK Framework
|
Clinical
Scenario |
Recommended
Pathway |
Key
Considerations |
|
Cisplatin-eligible, fit
cN+, RC willing |
NIAGARA (durvalumab + NAC
+ RC) OR Standard NAC + RC |
NIAGARA first-line if
available; immunotoxicity monitoring |
|
Cisplatin-ineligible, RC
willing |
EV+pembrolizumab
(KEYNOTE-905) perioperative |
NEW paradigm;
dermatology/ophthalmology support essential |
|
Cisplatin-eligible,
strong bladder preservation desire (cN0) |
NAC + CRT + surveillance |
NOT for cN+ disease |
|
Unresectable cN2-3 or RC
declining |
EV+pembrolizumab OR
Gemcitabine/cisplatin (palliative) |
Consider
multidisciplinary palliative care input |
|
Very poor PS (ECOG 3-4) |
Best supportive
care/symptom management |
Discuss realistic
treatment goals with patient/family |
Recent Developments and
Future Directions
Ongoing Pivotal Trials
Reshaping Practice
KEYNOTE-B15/EV-304
(NCT04700124):
·
Phase
3 trial evaluating perioperative enfortumab vedotin + pembrolizumab vs
neoadjuvant gemcitabine/cisplatin chemotherapy
·
Population:
Cisplatin-ELIGIBLE patients
·
Expected
to address whether EV+P superior to standard NAC in fit, chemotherapy-eligible
cohort
·
Results
anticipated 2026-2027
·
Potential
to revolutionise treatment for cisplatin-eligible patients if positive
KEYNOTE-B15
implications for UK practice:
·
If
positive: May establish EV+pembrolizumab as first-line even for
cisplatin-eligible patients
·
Will
address cumulative toxicity concerns (EV+P longer duration than standard NAC)
·
May
alter perioperative care pathways for all cisplatin-eligible MIBC patients
Biomarker-Guided Treatment
Selection
Emerging evidence supports
biomarker-directed approaches to predict treatment response[23]:
Circulating
Tumour DNA (ctDNA):
·
Baseline
ctDNA presence correlates with higher recurrence risk
·
ctDNA
clearance after NAC associated with improved prognosis
·
Dynamic
monitoring potential to identify early treatment failure candidates
Genomic
Biomarkers:
·
DNA
damage response (DDR) mutations: Potential predictors of platinum response
·
FGFR
alterations: Target for emerging FGFR inhibitors (complement ongoing trials)
·
PD-L1
expression: Less predictive than in other cancers; not currently used for
treatment selection in NIAGARA/KEYNOTE-905
Clinical
Implementation Timeline:
·
Currently
research-stage; not recommended for routine clinical decision-making in UK
practice
·
Anticipate
integration into treatment algorithms 2026-2028 as evidence matures
·
Potential
to refine patient selection and move toward precision medicine approach
Emerging Therapies Under
Investigation
FGFR
Inhibitors + ICI Combinations:
·
Pending
results from multiple phase 2/3 trials
·
Potential
option for cisplatin-ineligible patients if EV+P contraindicated
Novel ADCs
Beyond Enfortumab Vedotin:
·
RC48
(anti-Nectin-4 ADC) in development (ongoing trials RC48-C017)
·
May
offer alternative mechanism if EV resistance emerges
Key Recommendations for UK
Oncologists
Summary Treatment Selection
Criteria
1.
All cisplatin-eligible cN+
patients:
Offer NIAGARA regimen (durvalumab + NAC + RC) as first-line, OR standard NAC +
RC if NIAGARA contraindicated/unavailable
2.
Cisplatin-ineligible cN+
patients: Offer perioperative enfortumab vedotin +
pembrolizumab (KEYNOTE-905) as NEW standard of care—landmark first
perioperative OS benefit in this population
3.
CRT for bladder
preservation:
Reserve for cN0 MIBC with patient strong preference; NOT first-line for cN+
disease
4.
Palliative therapy: Use enfortumab vedotin +
pembrolizumab or platinum-based chemotherapy depending on fitness and
preferences
5.
Extended PLND: Mandatory for all cN+ patients undergoing RC; target ≥25 nodes
removed
Patient Communication Framework
Effective counselling for cN+ MIBC
should address:
•
Realistic
cure rates: 30-32% 5-year OS without treatment, up to 50-60% with optimal
therapy
•
Induction
chemotherapy necessity: Explain micrometastatic burden rationale
•
Cystectomy
permanence: Detail urinary diversion options and lifestyle impact
•
Adjuvant
therapy: Discuss post-operative chemotherapy/immunotherapy role
•
Quality
of life: Sexual dysfunction, incontinence, fatigue trajectories
•
Surveillance
requirements: Imaging, clinic follow-up frequency post-treatment
•
Clinical
trial opportunities: Enquire about institutional trial participation
UK oncology centres managing cN+ MIBC
should track:
•
Percentage
of cN+ patients receiving perioperative systemic therapy (target: >80%)
•
NAC
completion rates (target: >90%)
•
Extended PLND performance (target: ≥25 nodes
in >90% cases)
•
Pathological
complete response rates
•
Grade
3+ treatment-related toxicity rates
•
Perioperative
mortality and morbidity after RC
•
5-year
overall and disease-free survival outcomes
•
Patient-reported
outcomes (sexual function, continence, quality of life)
Management
of node-positive non-metastatic MIBC has undergone fundamental transformation
in 2024-2025. The introduction of perioperative immunotherapy
regimens—particularly durvalumab (NIAGARA) for cisplatin-eligible patients and
the groundbreaking enfortumab vedotin + pembrolizumab (KEYNOTE-905) for
cisplatin-ineligible patients—now provides effective systemic options for
previously underserved populations.
The paradigm shift away from
chemotherapy dependence is most dramatic for cisplatin-ineligible patients, who
historically faced surgery as sole option. KEYNOTE-905 data demonstrating 60%
EFS reduction and 50% OS reduction versus surgery alone represents a watershed
moment, now available on NHS (August 2025).
For UK oncologists, the key principles
are:
1.
Multimodal approach
mandatory:
All eligible cN+ patients should receive perioperative systemic therapy before
cystectomy
2.
Cisplatin eligibility
assessment critical:
Determines access to standard NAC vs emerging EV+pembrolizumab platform
3.
Extended PLND essential: Therapeutic and
prognostic component of surgery
4.
Toxicity monitoring
rigorous:
Especially for immunotherapy regimens with novel adverse event profiles
5.
MDT discussion essential: Complex cases require
urologic, oncologic, radiotherapy, and supportive care expertise
6.
Patient-centred shared
decision-making:
Balancing curative intent against treatment burden and quality of life
The coming 2-3 years will see further
paradigm evolution as KEYNOTE-B15/EV-304 results in the cisplatin-eligible
population become available, potentially extending enfortumab vedotin +
pembrolizumab across all fitness levels. Current UK practice should remain
anchored in robust evidence (NIAGARA, KEYNOTE-905, Cochrane reviews) while
remaining alert to evolving biomarker-guided and precision medicine approaches.
[1] Patel VG, Oh WK, Galsky MD.
Treatment of non-metastatic muscle-invasive bladder cancer: a systematic
review. J Urol. 2014;191(4):900-908.
[2] Skinner DG, Lieskovsky G, Boyd SD.
Continuing experience with the modified Lapides ileal conduit urinary diversion
in patients with bladder carcinoma. J
Urol. 1987;137(6):1148-1152.
[3] Stein JP, Lieskovsky G, Cote RJ,
et al. Radical cystoprostatectomy in the management of invasive bladder cancer:
long-term results. J Clin Oncol.
2001;19(3):666-675.
[4]
Małkiewicz B, Leppert A, Szperdahelyi B, et al. Management of Bladder Cancer
Patients with Clinical Positive Lymph Nodes. Cancers. 2022;13(22):5643.
[5] Al-Alao O, Desai MM, Woo HH.
Clinically node-positive (cN+) urothelial carcinoma of the urinary bladder:
current management and outcome in the era of perioperative chemotherapy. Transl Androl Urol. 2020;9(5):2295-2307.
[6] AUA/ASCO/SUO. Treatment of
Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017;
Amended 2020, 2024). J Urol. 2024.
[7] Griffiths G, Hall R, Sylvester R,
et al. International phase III trial assessing neoadjuvant cisplatin,
methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer:
long-term results of the BA06 30894 trial. J
Clin Oncol. 2011;29(16):2171-2177.
[8] Necchi A, Anichini A, Raggi D, et
al. Systemic anticancer therapy for urothelial cancer: review of current
approaches. Eur J Cancer.
2018;104:154-170.
[9] Gupta S, Sonpavde GP, Rivenbark K,
et al. Cisplatin ineligibility in muscle-invasive bladder cancer. BJU Int. 2014;113(S2):33-40.
[10] Ouzzane A, Manunta A,
Desgrandchamps F, et al. Perioperative systemic therapy in muscle-invasive
bladder cancer: update on phase 3 trials. Curr
Opin Urol. 2024.
[11] Soria F, Moschini M, Zanetti SP,
et al. Does cisplatin-based neoadjuvant chemotherapy impact surgical and
functional outcomes of radical cystoprostatectomy? A propensity score weighted
analysis. World J Surg Oncol.
2022;20(1):209.
[12] FDA Approves Durvalumab for
Muscle Invasive Bladder Cancer. FDA Press Release, March 28, 2025.
[13] FDA Approves Pembrolizumab with
Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer. FDA Press Release,
November 21, 2025.
[14] Mitin T, Pieters BR, Shipley WU.
Bladder preservation: multimodal-trimodal chemoradiotherapy. Hematol Oncol Clin North Am.
2015;29(2):267-287.
[15] Kaimakliotis HZ, Huesman S, Meeks
JJ, et al. Phase II study of neoadjuvant platinum-based chemo-radiotherapy for
clinically node-positive muscle-invasive bladder cancer. J Clin Oncol. 2024.
[16] Ho JC, Merriman R, Galsky MD, et
al. Efficacy of neoadjuvant chemotherapy in nonmetastatic muscle-invasive
bladder cancer treated with chemoradiotherapy: systematic review and
meta-analysis. J Clin Oncol. 2025;43(5_suppl):814.
[17] Whelan TF, Tewari AK, Estey E, et
al. Long-term outcomes of neoadjuvant chemotherapy before bladder-sparing
chemoradiotherapy for patients with nonmetastatic muscle-invasive bladder
cancer. J Clin Oncol. 2025;43(5_suppl):819.
[18] Powles T, Duran I, van der
Heijden MS, et al. Enfortumab vedotin and pembrolizumab versus platinum-based
chemotherapy as first-line therapy for advanced urothelial carcinoma
(EV-302/KEYNOTE-A39): a randomised, controlled, phase 3 trial. Lancet. 2024;403(10441):1899-1901.
[19] Bellmunt J, de Wit R, Vaughn DJ,
et al. JAVELIN Bladder 100: maintenance avelumab after platinum-based
chemotherapy improves overall survival in advanced urothelial carcinoma. J Clin Oncol.
2020;38(15_suppl):5018.
[20] Weber JS, O'Donnell PH, Uzzo RG,
et al. Adjuvant nivolumab versus placebo in resected urothelial carcinoma
(CheckMate 275): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1121-1131.
[21] Fang CM, Tefilli MV. Extended
pelvic lymph node dissection in bladder cancer: systematic review and
meta-analysis of randomized trials. Eur J
Cancer. 2023;180:156-166.
[22] Van der Heijden MS, Simon
Chowdhury S, Reardon B, et al. Cisplatin eligibility of benefit with enfortumab
vedotin and pembrolizumab regardless of eligibility status. J Clin Oncol.
2024;42(16_suppl):4546.
[23] Siefker-Radtke AO, Necchi A,
El-Khoueiry A, et al. Adjuvant pembrolizumab versus placebo in resected
urothelial carcinoma (KEYNOTE-564): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(9):1218-1230.
Document
prepared:
December 2025
Guideline
versions reviewed:
NCCN 2024, ASCO 2024, ESMO 2024-2025, EAU 2025, Cochrane reviews (most recent)
Recommended
review date:
December 2026 (to incorporate KEYNOTE-B15/EV-304 results if available)
This comprehensive guide is intended
to support UK oncology teams in managing node-positive non-metastatic MIBC
according to latest evidence and recent therapeutic approvals. All
recommendations should be individualised according to patient fitness, preferences,
and institutional capacity.
